Ponazuril

Ponazuril
Clinical data
Trade namesMarquis
Other namesACD855; ACD-855
AHFS/Drugs.comFDA Professional Drug Information
Routes of
administration		Oral
ATCvet code
Legal status
Legal status
Identifiers
  • 1-Methyl-3-[3-methyl-4-[4-(trifluoromethylsulfonyl)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.157.907 Edit this at Wikidata
Chemical and physical data
FormulaC18H14F3N3O6S
Molar mass457.38 g·mol−1
3D model (JSmol)
  • CC1=C(C=CC(=C1)N2C(=O)NC(=O)N(C2=O)C)OC3=CC=C(C=C3)S(=O)(=O)C(F)(F)F
  • InChI=1S/C18H14F3N3O6S/c1-10-9-11(24-16(26)22-15(25)23(2)17(24)27)3-8-14(10)30-12-4-6-13(7-5-12)31(28,29)18(19,20)21/h3-9H,1-2H3,(H,22,25,26) ☒N
  • Key:VBUNOIXRZNJNAD-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Ponazuril (INN), sold by Merial, Inc.,[1] now part of Boehringer Ingelheim,[2] under the trade name Marquis® (15% w/w ponazuril), is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by coccidia Sarcocystis neurona.[3][4] Veterinarians have been preparing a formulary version of the medication for use in small animals such as cats, dogs, and rabbits against coccidia as an intestinal parasite. Coccidia treatment in small animals is far shorter than treatment for EPM.[citation needed] Along with its analogue ACD856, ponazuril (also known as ACD855) is a positive allosteric modulator of the tropomyosin receptor kinases TrkA and TrkB.[5]

  1. ^ "Merial Acquires LEGEND® and MARQUIS®". Boehringer Ingelheim. Retrieved 2018-04-30.
  2. ^ "Sanofi and Boehringer Ingelheim confirm Closing of business swap | www.boehringer-ingelheim.com". boehringer-ingelheim.com. Retrieved 2018-04-30.
  3. ^ "Marquis". Drugs.com.
  4. ^ Mackay RJ, Tanhauser ST, Gillis KD, Mayhew IG, Kennedy TJ (March 2008). "Effect of intermittent oral administration of ponazuril on experimental Sarcocystis neurona infection of horses". American Journal of Veterinary Research. 69 (3): 396–402. doi:10.2460/ajvr.69.3.396. PMID 18312139.
  5. ^ Dahlström M, Madjid N, Nordvall G, Halldin MM, Vazquez-Juarez E, Lindskog M, Sandin J, Winblad B, Eriksdotter M, Forsell P (July 2021). "Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction". Cells. 10 (8): 1871. doi:10.3390/cells10081871. PMC 8391421. PMID 34440640.